Dexcom Faces Class Action Lawsuits
Analysis based on 43 articles · First reported Oct 30, 2025 · Last updated Dec 26, 2025
The ongoing class action lawsuits against Dexcom by Rosen Law Firm and Kessler Topaz Meltzer & Check, alleging unauthorized design changes and misleading statements, are likely to negatively impact Dexcom's stock price and market reputation. Investors are facing potential losses due to the alleged securities fraud, and the company faces increased regulatory scrutiny from the United States — Food and Drug Administration.
Dexcom, a publicly traded company, is facing multiple class action lawsuits filed by Rosen Law Firm and Kessler Topaz Meltzer & Check. These lawsuits allege that Dexcom made material design changes to its G6 and G7 continuous glucose monitoring systems without authorization from the United States — Food and Drug Administration. These changes purportedly rendered the devices less reliable, posing health risks to users and leading to overstated claims about the G7's enhancements, reliability, accuracy, and functionality. The lawsuits claim that Dexcom downplayed the severity of these issues, exposing the company to heightened regulatory scrutiny, enforcement actions, and significant legal, reputational, and financial harm. Investors who purchased Dexcom securities between July 26, 2024, and September 17, 2025, are encouraged to join the class actions, with lead plaintiff deadlines set for December 26 and December 29, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard